4-N-hydroxy-1-N-[(E)-[3-[11-[3-[(E)-[[4-(hydroxycarbamoyl)benzoyl]hydrazinylidene]methyl]phenoxy]undecoxy]phenyl]methylideneamino]benzene-1,4-dicarboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-N-hydroxy-1-N-[(E)-[3-[11-[3-[(E)-[[4-(hydroxycarbamoyl)benzoyl]hydrazinylidene]methyl]phenoxy]undecoxy]phenyl]methylideneamino]benzene-1,4-dicarboxamide
• 化学式: C₄₁H₄₆N₆O₈
• 分子量: 750.8
• InChiKey: ACUVVEBVNNHJPG-BITFRASFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  55
• 可旋转键数：
  22
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  200
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20140187510A1

  公开（公告）日：2014-07-03

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.